The agency formulated its advice to manufacturers after coordinating with the CDC and Defense Department. An advisory meeting ...

President Trump’s nominee to run the FDA secured the Senate HELP Committee’s backing. Elsewhere, Sutro cut jobs and a cell ...

Pheiron and Ribo are excited to announce that the first two strategic collaboration milestones have been successfully ...

The joint venture with generative AI firm Hologen hands MeiraGTx $200 million up front as well as other financial perks — a ...

The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic ...

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs ...

Funded by investors such as Flagship and General Catalyst, the AI startup claims its platform will help scientists speed up ...

Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.

Industry insiders are pushing to fix the small molecule ‘penalty’ by setting their hopes on a Republican majority.

Kelly, who made several key hires at the CDRH and helped negotiate the last user fee agreement, announced his departure in a ...